share_log

Emergent BioSolutions | 10-Q: Q3 2024 Earnings Report

Emergent BioSolutions | 10-Q: Q3 2024 Earnings Report

Emergent BioSolutions | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/08 01:34

Moomoo AI 已提取核心信息

Emergent BioSolutions reported Q3 2024 revenues of $293.8 million, up 9% year-over-year. Net income was $114.8 million compared to a net loss of $263.4 million in Q3 2023. The company's MCM Products segment saw strong growth with revenues up 62% to $174.2 million.Emergent made significant progress in improving its financial position during the quarter. It entered into a new $250 million Term Loan Agreement and a $100 million Revolving Credit Agreement. The company also generated cash through asset sales, including $75 million from the sale of RSDL and $35 million from the sale of its Baltimore-Camden facility.Looking ahead, Emergent believes it has alleviated substantial doubt about its ability to continue as a going concern. With $149.9 million in cash and $100 million available under its credit facility as of September 30, the company expects its liquidity sources to be adequate to fund operations for at least the next 12 months. However, Emergent noted ongoing risks and uncertainties related to product sales and development programs.
Emergent BioSolutions reported Q3 2024 revenues of $293.8 million, up 9% year-over-year. Net income was $114.8 million compared to a net loss of $263.4 million in Q3 2023. The company's MCM Products segment saw strong growth with revenues up 62% to $174.2 million.Emergent made significant progress in improving its financial position during the quarter. It entered into a new $250 million Term Loan Agreement and a $100 million Revolving Credit Agreement. The company also generated cash through asset sales, including $75 million from the sale of RSDL and $35 million from the sale of its Baltimore-Camden facility.Looking ahead, Emergent believes it has alleviated substantial doubt about its ability to continue as a going concern. With $149.9 million in cash and $100 million available under its credit facility as of September 30, the company expects its liquidity sources to be adequate to fund operations for at least the next 12 months. However, Emergent noted ongoing risks and uncertainties related to product sales and development programs.
Emergent BioSolutions报告2024年第三季度收入为29380万美元，同比增长9%。净利润为11480万美元，而2023年第三季度则净亏损26340万美元。该公司的MCm产品部门增长强劲，收入增长62%，达到17420万美元。Emergent在改善其财务状况方面在本季度取得了重大进展。它签署了一项新的25000万美元的定期贷款协议和一项10000万美元的循环信贷协议。公司还通过资产出售产生现金，包括从出售RSDL获得7500万美元，以及从出售其巴尔的摩—坎登设施获得3500万美元。展望未来，Emergent认为它已减轻了关于其持续经营能力的重大疑虑。截至9月30日，公司现金为14990万美元，信用额度可用10000万美元，预计其流动性来源足以支持至少接下来的12个月运营。然而，Emergent指出与产品销售和开发计划相关的持续风险和不确定性。
Emergent BioSolutions报告2024年第三季度收入为29380万美元，同比增长9%。净利润为11480万美元，而2023年第三季度则净亏损26340万美元。该公司的MCm产品部门增长强劲，收入增长62%，达到17420万美元。Emergent在改善其财务状况方面在本季度取得了重大进展。它签署了一项新的25000万美元的定期贷款协议和一项10000万美元的循环信贷协议。公司还通过资产出售产生现金，包括从出售RSDL获得7500万美元，以及从出售其巴尔的摩—坎登设施获得3500万美元。展望未来，Emergent认为它已减轻了关于其持续经营能力的重大疑虑。截至9月30日，公司现金为14990万美元，信用额度可用10000万美元，预计其流动性来源足以支持至少接下来的12个月运营。然而，Emergent指出与产品销售和开发计划相关的持续风险和不确定性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    cbdMD
    YCBD
    -- 0.5775
    Lifecore Biomedical
    LFCR
    -- 7.620
    IM Cannabis
    IMCC
    -- 2.530
    Cyclo Therapeutics
    CYTH
    -- 0.665
    Sunshine Biopharma
    SBFM
    -- 3.4600

    解锁榜首股票